The content pertains to the “Enterprise Taxonomy” focused on “Population and Public HealthCare.” It includes node settings to exclude this information from the Accelerate RSS feed, suggesting it is internally organized for specific purposes within the enterprise structure.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
